CN107922489B - κ骨髓瘤抗原嵌合性抗原受体和其用途 - Google Patents

κ骨髓瘤抗原嵌合性抗原受体和其用途 Download PDF

Info

Publication number
CN107922489B
CN107922489B CN201680031653.3A CN201680031653A CN107922489B CN 107922489 B CN107922489 B CN 107922489B CN 201680031653 A CN201680031653 A CN 201680031653A CN 107922489 B CN107922489 B CN 107922489B
Authority
CN
China
Prior art keywords
car
domain
cells
cell
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680031653.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922489A (zh
Inventor
肯尼斯·米克尔斯维特
罗莎娜·邓恩
大卫·戈特利布
格兰特·洛根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemalogix Pty Ltd
Original Assignee
Haemalogix Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemalogix Pty Ltd filed Critical Haemalogix Pty Ltd
Publication of CN107922489A publication Critical patent/CN107922489A/zh
Application granted granted Critical
Publication of CN107922489B publication Critical patent/CN107922489B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680031653.3A 2015-04-23 2016-04-25 κ骨髓瘤抗原嵌合性抗原受体和其用途 Active CN107922489B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562151968P 2015-04-23 2015-04-23
US62/151,968 2015-04-23
US201562158407P 2015-05-07 2015-05-07
US62/158,407 2015-05-07
PCT/US2016/029203 WO2016172703A2 (en) 2015-04-23 2016-04-25 Kappa myeloma antigen chimeric antigen receptors and uses thereof

Publications (2)

Publication Number Publication Date
CN107922489A CN107922489A (zh) 2018-04-17
CN107922489B true CN107922489B (zh) 2022-02-25

Family

ID=57143653

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680031653.3A Active CN107922489B (zh) 2015-04-23 2016-04-25 κ骨髓瘤抗原嵌合性抗原受体和其用途

Country Status (18)

Country Link
US (2) US11305011B2 (enExample)
EP (2) EP4368641A3 (enExample)
JP (3) JP7229768B2 (enExample)
KR (1) KR102623427B1 (enExample)
CN (1) CN107922489B (enExample)
AU (1) AU2016253126B2 (enExample)
BR (1) BR112017022838A2 (enExample)
CA (1) CA2978964A1 (enExample)
DK (1) DK3286223T5 (enExample)
ES (1) ES2976236T3 (enExample)
FI (1) FI3286223T3 (enExample)
HK (1) HK1252854A1 (enExample)
HR (1) HRP20240415T1 (enExample)
HU (1) HUE065799T2 (enExample)
IL (1) IL255207B2 (enExample)
PT (1) PT3286223T (enExample)
RU (1) RU2743188C2 (enExample)
WO (1) WO2016172703A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4368641A3 (en) 2015-04-23 2024-08-14 HaemaLogiX Ltd. Kappa myeloma antigen chimeric antigen receptors and uses thereof
CN107529550A (zh) * 2017-08-28 2018-01-02 马晓冬 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法
WO2019047932A1 (zh) * 2017-09-08 2019-03-14 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
WO2019108932A1 (en) * 2017-11-30 2019-06-06 Haemalogix Pty. Ltd. Methods for expanding kappa myeloma antigen chimeric antigen receptors expressing cells
WO2019201995A1 (en) * 2018-04-20 2019-10-24 Medizinische Hochschule Hannover Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
US20220177573A1 (en) 2018-07-09 2022-06-09 Oslo Universitetssykehus Hf Two chimeric antigen receptors specifically binding cd19 and igkappa
CN110832071A (zh) * 2018-09-14 2020-02-21 上海原能细胞医学技术有限公司 表面包含免疫调节剂的细胞及其用途
EP3890780A4 (en) * 2018-12-03 2022-08-17 HaemaLogiX Pty Ltd. METHOD OF TREATMENT
US20220175833A1 (en) * 2019-03-07 2022-06-09 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
KR20220012328A (ko) * 2019-05-24 2022-02-03 포티 세븐, 인코포레이티드 c-kit 및 CD47에 대한 면역요법제의 병용 투여를 위한 요법
CN110305906B (zh) * 2019-07-18 2021-11-12 山东大学第二医院 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞
KR20220137882A (ko) * 2019-12-05 2022-10-12 바이셀릭스, 인크. 보편적 세포 요법을 위한 면역 회피 기작의 조절제
CA3176109A1 (en) * 2020-03-27 2021-09-30 Haemalogix Pty Ltd Composition and method
IL297851A (en) 2020-05-04 2023-01-01 Saliogen Therapeutics Inc Transposition-based treatments
WO2021232200A1 (en) * 2020-05-18 2021-11-25 Guangdong Tcrcure Biopharma Technology Co., Ltd. Il-12 armored immune cell therapy and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022268196A1 (zh) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 靶向gpc3的抗原结合蛋白
WO2023010118A1 (en) * 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
KR102789265B1 (ko) * 2022-04-14 2025-04-02 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법
WO2024196796A1 (en) * 2023-03-17 2024-09-26 Cartesian Therapeutics, Inc. Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551783A (zh) * 2001-07-06 2004-12-01 ���ɿ������޹�˾ 治疗多发性骨髓瘤的方法
CN102802667A (zh) * 2009-04-07 2012-11-28 免疫系统治疗有限公司 用于治疗免疫失调的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2507080C (en) * 2002-11-27 2015-01-06 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
WO2007019406A2 (en) * 2005-08-04 2007-02-15 The Regents Of The University Of California Methods for treating and detecting beta-cell disease
WO2010135655A2 (en) * 2009-05-21 2010-11-25 Stratatech Corporation Human skin substitutes expressing il-12
US9212229B2 (en) 2010-09-08 2015-12-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN104177499B (zh) * 2013-05-27 2019-01-08 上海雅科生物科技有限公司 一种嵌合抗原受体、编码基因、表达载体及其应用
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015164739A1 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
EP4368641A3 (en) 2015-04-23 2024-08-14 HaemaLogiX Ltd. Kappa myeloma antigen chimeric antigen receptors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551783A (zh) * 2001-07-06 2004-12-01 ���ɿ������޹�˾ 治疗多发性骨髓瘤的方法
CN102802667A (zh) * 2009-04-07 2012-11-28 免疫系统治疗有限公司 用于治疗免疫失调的方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Costimulation by chimeric antigen receptors revisited: the T cell antitumor response benefits from combined CD28-OX40 signalling;Andreas A. Hombach等;《International Journal of Cancer》;20110203;第129卷(第12期);摘要，第2935-2936页 *
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma;Leonardo Mirandola等;《PLoS One》;20110713;第6卷(第7期);摘要，第2-6页结果部分 *
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment;Ling Zhang等;《Molecular Therapy》;20110201;第19卷(第4期);摘要，第751页背景，第752页结果部分 *
Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death;Anna Demartis等;《CANCER RESEARCH》;19960815;第56卷(第18期);摘要，第4215-4217页结果部分 *
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma;Patnaik et al.;《British Journal of Cancer》;20140731;第111卷(第2期);摘要部分，第273页左栏第4段 *
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells;Juan Vera等;《Blood》;20061201;第108卷(第12期);摘要，第3891页左栏第2段-第3892页结果部分 *

Also Published As

Publication number Publication date
EP4368641A3 (en) 2024-08-14
FI3286223T3 (fi) 2024-03-25
EP3286223B1 (en) 2024-02-28
DK3286223T3 (da) 2024-04-02
RU2743188C2 (ru) 2021-02-16
JP7229768B2 (ja) 2023-02-28
NZ735778A (en) 2024-03-22
HRP20240415T1 (hr) 2025-05-23
WO2016172703A2 (en) 2016-10-27
BR112017022838A2 (pt) 2018-07-17
RU2017138528A (ru) 2019-05-07
AU2016253126A1 (en) 2017-10-12
EP3286223A2 (en) 2018-02-28
RU2017138528A3 (enExample) 2019-09-03
IL255207A0 (en) 2017-12-31
JP2023024793A (ja) 2023-02-16
CN107922489A (zh) 2018-04-17
HUE065799T2 (hu) 2024-06-28
EP3286223A4 (en) 2018-12-05
US20220193232A1 (en) 2022-06-23
ES2976236T3 (es) 2024-07-29
EP3286223B8 (en) 2024-04-03
DK3286223T5 (da) 2024-10-07
KR102623427B1 (ko) 2024-01-12
US20180228892A1 (en) 2018-08-16
KR20170139044A (ko) 2017-12-18
IL255207B2 (en) 2023-09-01
CA2978964A1 (en) 2016-10-27
HK1252854A1 (zh) 2019-06-06
JP2021073312A (ja) 2021-05-13
PT3286223T (pt) 2024-03-22
AU2016253126B2 (en) 2020-01-30
HK1251586A1 (en) 2019-02-01
EP4368641A2 (en) 2024-05-15
US11305011B2 (en) 2022-04-19
WO2016172703A3 (en) 2016-11-24
IL255207B1 (en) 2023-05-01
JP2018519356A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
CN107922489B (zh) κ骨髓瘤抗原嵌合性抗原受体和其用途
JP7114490B2 (ja) キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US20210403885A1 (en) Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
CN110944652A (zh) T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途
US20190359723A1 (en) Antibody targeting il-13ra2 and use thereof
WO2019222796A1 (en) Chimeric antigen receptors with modified linker domains and uses thereof
EP3293199B1 (en) Chimeric antigen receptors
US12269861B2 (en) Chimeric ILT receptor compositions and methods
KR20200039783A (ko) Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
WO2019108932A1 (en) Methods for expanding kappa myeloma antigen chimeric antigen receptors expressing cells
EP4532022A1 (en) Anti-steap1 car
WO2018149358A1 (zh) 靶向il-13ra2的抗体及其应用
HK40112160A (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
HK1251586B (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
WO2023044304A1 (en) Chimeric adaptor and kinase signaling proteins and their use in immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252854

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant